Shopping Cart

Visceral Pain-Pipeline Review, H1 2016

SKU
GMDHC7727IDB
READ MORE
USD 2,000
Single User License
USD 2,000
Site License
USD 4,000
Corporate User License
USD 6,000

Summary

Global Markets Direct's, 'Visceral Pain-Pipeline Review, H1 2016', provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visce

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Summary

Global Markets Direct's, 'Visceral Pain-Pipeline Review, H1 2016', provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Visceral Pain

The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects

The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Visceral Pain

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Visceral Pain Overview 8

Therapeutics Development 9

Pipeline Products for Visceral Pain-Overview 9

Pipeline Products for Visceral Pain-Comparative Analysis 10

Visceral Pain-Therapeutics under Development by Companies 11

Visceral Pain-Therapeutics under Investigation by Universities/Institutes 12

Visceral Pain-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Visceral Pain-Products under Development by Companies 15

Visceral Pain-Products under Investigation by Universities/Institutes 16

Visceral Pain-Companies Involved in Therapeutics Development 17

Addex Therapeutics Ltd 17

Amorepacific Corporation 18

Aros Pharma ApS 19

Astellas Pharma Inc. 20

Echo Pharmaceuticals B.V. 21

GIcare Pharma Inc 22

Grunenthal GmbH 23

Nektar Therapeutics 24

Neurim Pharmaceuticals Ltd 25

Visceral Pain-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

ADX-71441-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ADX-71743-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ASP-7663-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

dronabinol-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

GIC-1002-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

NEO-5024-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

NEO-5937-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

NeuP-12-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

NKTR-195-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

PAC-14028-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

piromelatine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

PPC-5650-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

PR-38-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

RO-656570-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecule to Block Nav1.9 Channel for Pain-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

URB-937-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Visceral Pain-Recent Pipeline Updates 56

Visceral Pain-Dormant Projects 60

Visceral Pain-Discontinued Products 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64


List Of Figure

List of Figures

Number of Products under Development for Visceral Pain, H1 2016 9

Number of Products under Development for Visceral Pain-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Top 10 Targets, H1 2016 27

Number of Products by Stage and Top 10 Targets, H1 2016 27

Number of Products by Top 10 Mechanism of Actions, H1 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29

Number of Products by Routes of Administration, H1 2016 31

Number of Products by Stage and Routes of Administration, H1 2016 31

Number of Products by Molecule Types, H1 2016 33

Number of Products by Stage and Molecule Types, H1 2016 33


List Of Table

List of Tables

Number of Products under Development for Visceral Pain, H1 2016 9

Number of Products under Development for Visceral Pain-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Clinical Stage Development, H1 2016 13

Comparative Analysis by Early Stage Development, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Investigation by Universities/Institutes, H1 2016 16

Visceral Pain-Pipeline by Addex Therapeutics Ltd, H1 2016 17

Visceral Pain-Pipeline by Amorepacific Corporation, H1 2016 18

Visceral Pain-Pipeline by Aros Pharma ApS, H1 2016 19

Visceral Pain-Pipeline by Astellas Pharma Inc., H1 2016 20

Visceral Pain-Pipeline by Echo Pharmaceuticals B.V., H1 2016 21

Visceral Pain-Pipeline by GIcare Pharma Inc, H1 2016 22

Visceral Pain-Pipeline by Grunenthal GmbH, H1 2016 23

Visceral Pain-Pipeline by Nektar Therapeutics, H1 2016 24

Visceral Pain-Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 25

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Stage and Target, H1 2016 28

Number of Products by Stage and Mechanism of Action, H1 2016 30

Number of Products by Stage and Route of Administration, H1 2016 32

Number of Products by Stage and Molecule Type, H1 2016 34

Visceral Pain Therapeutics-Recent Pipeline Updates, H1 2016 56

Visceral Pain-Dormant Projects, H1 2016 60

Visceral Pain-Dormant Projects (Contd..1), H1 2016 61

Visceral Pain-Discontinued Products, H1 2016 62

To know more information on Purchase by Section, please send a mail to

Products

Visceral Pain Therapeutic Products under Development, Key Players in Visceral Pain Therapeutics, Visceral Pain Pipeline Overview, Visceral Pain Pipeline, Visceral Pain Pipeline Assessment

Companies

Addex Therapeutics Ltd Amorepacific Corporation Aros Pharma ApS Astellas Pharma Inc. Echo Pharmaceuticals B.V. GIcare Pharma Inc Grunenthal GmbH Nektar Therapeutics Neurim Pharmaceuticals Ltd

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.